LEADER 05588nam 2200733 a 450 001 9910829127903321 005 20240313235028.0 010 $a9781118648759 (electronic book) 010 $a9781118648759 010 $a1118648757 010 $a9781118648735 010 $a1118648730 010 $a9781118648742 010 $a1118648749 035 $a(CKB)2560000000103958 035 $a(EBL)1215808 035 $a(OCoLC)851159947 035 $a(SSID)ssj0000973112 035 $a(PQKBManifestationID)11616142 035 $a(PQKBTitleCode)TC0000973112 035 $a(PQKBWorkID)10960080 035 $a(PQKB)10620964 035 $a(MiAaPQ)EBC1215808 035 $a(Au-PeEL)EBL1215808 035 $a(CaPaEBR)ebr10720694 035 $a(CaONFJC)MIL499123 035 $a(OCoLC)812570985 035 $a(FINmELB)ELB179070 035 $a(Perlego)1001278 035 $a(EXLCZ)992560000000103958 100 $a20130621d2013 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aVehicular networks $emodels and algorithms /$fedited by Andre?-Luc Beylot, Houda Labiod ; series editor, Guy Pujolle 205 $a1st ed. 210 $aLondon $cISTE$d[2013] 215 $a1 online resource (284 pages) 225 0$aNetworks and telecommunications series 300 $aDescription based upon print version of record. 311 08$a9781848214897 311 08$a1848214898 320 $aIncludes bibliographical references and index. 327 $aCover; Title Page; Contents; Introduction; Chapter 1. Congestion Control for Safety Vehicular Ad Hoc Networks; 1.1. Introduction; 1.2. Beaconing frequency; 1.3. Data rate; 1.4. Transmission power; 1.5. Minimum contention window; 1.6. Physical carrier sense; 1.7. Conclusion; 1.8. Bibliography; Chapter 2. Inter-Vehicle Communication for the Next Generation of Intelligent Transport Systems: Trends in Geographic Ad HocRouting Techniques; 2.1. Introduction; 2.2. IVC-relating ITS projects; 2.3. Wireless sublayer techniques; 2.3.1. WLAN and WPAN (up to 300 m) 327 $a2.3.2. Dedicated short-range communication (up to 1 km)2.3.3. Cellular networks (more than 1 km); 2.3.4. Comparison; 2.4. Geographic routing techniques for VANET; 2.4.1. Features of VANET; 2.4.2. Localization; 2.4.3. Unicast greedy routing; 2.4.4. Geocast (multicast) routing; 2.4.5. Delay tolerant network-based routing; 2.4.6. Map-based routing; 2.5. Conclusion and open issues; 2.6. Acknowledgments; 2.7. Bibliography; Chapter 3. CONVOY: A New Cluster-Based Routing Protocol for Vehicular Networks; 3.1. Introduction; 3.2. Clustering or network partitioning 327 $a3.2.1. General remarks on the partitioning of mobile ad hoc networks 3.2.2. Controlling the number of hops; 3.2.3. Controlling the number of nodes; 3.2.4. Role of the clusterhead; 3.3. Mobility-based clustering in ad hoc vehicular networks; 3.3.1. The dynamics of vehicular traffic in VANETs; 3.3.2. Clustering according to the lane; 3.3.3. Clustering depending on the relative speed between the vehicles; 3.3.4. Clustering depending on the direction of the movement (movement-based); 3.3.5. Clustering depending on the radio link quality; 3.3.6. Clustering depending on speed and relative speed 327 $a3.3.7. Clustering depending on the position,speed and direction 3.4. Clustering of VANETs for MAC and transport applications; 3.4.1. Cluster-based MAC protocol; 3.4.2. Clustering for transport applications; 3.5. CONVOY: a vehicle convoy formation protocol; 3.5.1. Intra-convoy communication protocol; 3.5.2. Convoy formation algorithm; 3.6. Assessment of the convoy formation protocol; 3.6.1. Optimal parameters of the algorithm; 3.6.2. Distribution of the length of convoys; 3.6.3. Convoy stability; 3.7. Conclusion; 3.8. Bibliography 327 $aChapter 4. Complementarity between Vehicular Networks and LTE Networks 4.1. Introduction; 4.2. State of the art; 4.3. General description of the proposed architecture; 4.3.1. Network organization mechanisms for areas completely covered by LTE; 4.3.2. Network organization mechanisms forareas that are not completely covered by LTE; 4.3.3. Information collection application: LTE4V2X-C; 4.3.4. Information dissemination application:LTE4V2X-D; 4.4. Detailed description of the LTE4V2X-C protocol; 4.4.1. Initialization phase; 4.4.2. Maintenance; 4.4.3. Extension for the areas not covered by the LTE 327 $a4.5. A detailed description of the LTE4V2X-D protocol 330 $aOver the last few years vehicular networks have been receiving a lot of attention from academia, industry, standardization bodies, and the various transportation agencies and departments of many governments around the world. It is envisaged in the next decade that the Intelligent Transportation System (ITS) will become an essential part of our daily life. This book describes models and/or algorithms designed to investigate evolutionary solutions to overcome important issues such as congestion control, routing, clustering, interconnection with long-term evolution (LTE) and LTE advanced cellular 410 0$aISTE 606 $aVehicular ad hoc networks (Computer networks) 615 0$aVehicular ad hoc networks (Computer networks) 701 $aBeylot$b Andre-Luc$0975716 701 $aLabiod$b Houda$0935097 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910829127903321 996 $aVehicular networks$92221856 997 $aUNINA LEADER 04133nam 22006133 450 001 9911019785503321 005 20241207060246.0 010 $a9783527838387 010 $a3527838384 010 $a9783527838394 010 $a3527838392 010 $a9783527838370 010 $a3527838376 035 $a(MiAaPQ)EBC31812765 035 $a(Au-PeEL)EBL31812765 035 $a(CKB)36822877300041 035 $a(OCoLC)1477220064 035 $a(Perlego)4668906 035 $a(Exl-AI)31812765 035 $a(EXLCZ)9936822877300041 100 $a20241207d2025 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aTrends in MRNA Vaccine Research 205 $a1st ed. 210 1$aNewark :$cJohn Wiley & Sons, Incorporated,$d2025. 210 4$dİ2025. 215 $a1 online resource (428 pages) 225 1 $aTrends in Drug Discovery Series 311 08$a9783527350582 311 08$a3527350586 327 $aCover -- Title Page -- Copyright -- Contents -- Preface -- Preface from the Volume Editors -- Part I How mRNA Vaccines Work -- Chapter 1 A Historical Overview on mRNA Vaccine Development -- 1.1 Introduction -- 1.2 The Path of mRNA as an Unstable and Toxic Product to a New Class of Medicine -- 1.2.1 The Discovery and In Vitro Production of mRNA -- 1.2.2 The Inflammatory Nature of mRNA -- 1.3 How Studying Lipid Bilayer Structures in Cell Membranes Gave Rise to the Eventual Development of Lipid Nanoparticles for RNA Delivery -- 1.3.1 From Biological Cell Membranes to Liposomal Drugs -- 1.3.2 Ionizable Lipid Nanoparticles for Systemic Delivery of Nucleic Acids -- 1.4 The Journey of Developing Clinical mRNA Vaccines -- 1.5 Concluding Remarks -- References -- Chapter 2 Immune Responses to mRNA Vaccine -- 2.1 Introduction -- 2.2 Innate Sensing of RNA Molecules -- 2.3 Innate Immune Response to mRNA Vaccines -- 2.3.1 Innate Immune Response in Humans -- 2.3.2 Tissue Innate Immune Response in Mice -- 2.4 mRNA Design and Innate Immunity -- 2.4.1 Cap -- 2.4.2 Untranslated Regions -- 2.4.3 Poly(A) -- 2.4.4 Coding Sequence -- 2.5 Optimization and Production of mRNA for an Adequate Innate Immune Response$7Generated by AI. 330 8 $aThe authoritative guide to the revolutionary concept behind the successful Covid-19 vaccines In Trends in mRNA Vaccine Research, a team of distinguished researchers delivers a practical and up-to-date discussion of the biochemical and biomedical foundations of mRNA vaccines. They also explore the manufacturing conditions required for successful vaccine development and review recent progress in a variety of medical fields, including vaccines against pathogens like SARS-CoV-2, HIV, plasmodium, Mycobacterium tuberculosis, as well as anticancer vaccines. Volume highlights include: * A historical overview of mRNA vaccine development * Immune responses to modified or unmodified mRNA vaccines * A description of the different mRNA vaccine platforms * Latest data on current mRNA vaccine developments against infectious diseases and cancer Perfect for medicinal chemists, immunologists, and epidemiologists, Trends in mRNA Vaccine Research will also benefit researchers and scientists working in the pharmaceutical industry, as well as cancer researchers with an interest in vaccine development. 410 0$aTrends in Drug Discovery Series 606 $aCOVID-19 vaccines$7Generated by AI 606 $aMessenger RNA$7Generated by AI 615 0$aCOVID-19 vaccines 615 0$aMessenger RNA 676 $a615.372 700 $aSzabo$b Gabor Tamas$01842735 701 $aPardi$b Norbert$01842736 701 $aFischer$b Ja?nos$0881301 701 $aKlein$b Christian$0426675 701 $aChilders$b Wayne E$01838514 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911019785503321 996 $aTrends in MRNA Vaccine Research$94422945 997 $aUNINA